The Korea Times
Biotech giant Alteogen’s move toward a KOSPI listing transfer is fueling concerns within the venture capital industry and the Kosdaq market that the secondary bourse could become even more marginalized, according to industry officials and analysts Wednesday. The sense of crisis comes amid an unprecedented divergence in returns between the country’s main bourse, the KOSPI, and the Kosdaq. While the benchmark index has been driven higher by semiconductor heavyweights such as Samsung Electronics and SK hynix, major Kosdaq sectors, including biotech and battery stocks, have struggled to maintain momentum. Earlier in the day, the Korea Venture Capital Association, the Kosdaq Association and the Korea Venture Business Association released a joint statement calling on leading Kosdaq-listed companies to remain on the market, warning that the departure of blue-chip firms could weaken investor confidence and undermine the broader innovation ecosystem. The joint appeal by the three organizations is widely seen as a response to Alteogen’s planned move to the KOSPI. The biotech firm, currently
Go to News Site